

Connecting via Winsock to STN

*structure search*

*10/629,858*

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID:sssptau121bd

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'REGISTRY' AT 14:29:28 ON 29 SEP 2004

FILE 'REGISTRY' ENTERED AT 14:29:28 ON 29 SEP 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

=> s warfrin/cn

L2 0 WARFRIN/CN

=> s warfarin/cn

L3 1 WARFARIN/CN

=> d ide

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 81-81-2 REGISTRY

CN 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Coumarin, 3-( $\alpha$ -acetonylbenzyl)-4-hydroxy- (7CI, 8CI)

OTHER NAMES:

CN ( $\pm$ )-Warfarin

CN ( $\pm$ )-Warfarin-alcohol

CN (RS)-Warfarin

CN 1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone

CN 3-( $\alpha$ -Acetonylbenzyl)-4-hydroxycoumarin

CN 3-( $\alpha$ -Phenyl- $\beta$ -acetylethyl)-4-hydroxycoumarin

CN 3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin

CN 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one

CN Athrombine-K

CN Brumolin

CN Co-Rax

CN Compound 42

CN Coumafen

CN Coumafene

CN Coumaphen

CN Coumefene

CN Dethmor

CN DL-3-( $\alpha$ -Acetonylbenzyl)-4-hydroxycoumarin

CN Kumader

CN Kumadu

CN Kumatox

CN NSC 59813

CN rac-Warfarin

CN Ratron

CN Ratron G

CN Rodafarin

CN Rodafarin C

CN Rodex


CN Temus W

CN Vampirinip II

CN Vampirinip III

CN W.A.R.F. 42


CN WARF compound 42  
 CN Warfarin  
 CN Zoocoumarin  
 FS 3D CONCORD  
 DR 56573-89-8, 5543-56-6  
 MF C19 H16 O4  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS,  
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,  
 CEN, CHEMCATS, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DIOGENES, EMBASE,  
 HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK\*,  
 MSDS-OHS, NIOSHTIC, PIRA, PROMT, PS, RTECS\*, SPECINFO, TOXCENTER,  
 ULIDAT, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent;  
 Report  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
 reagent); USES (Uses); NORL (No role in record)  
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological  
 study); PREP (Preparation); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU  
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
 (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical  
 study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC  
 (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties);  
 USES (Uses)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


3490 REFERENCES IN FILE CA (1907 TO DATE)  
 49 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 3507 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> str  
 :gra r66,dis



:=> d sia  
 L4 HAS NO ANSWERS

L4 STR



NODE ATTRIBUTES:

HCOUNT IS E1 AT 12  
HCOUNT IS E2 AT 13  
HCOUNT IS E3 AT 15  
HCOUNT IS E2 AT 18  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> s 14

SAMPLE SEARCH INITIATED 14:36:12 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s 14 ful

FULL SEARCH INITIATED 14:37:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 75 TO ITERATE

100.0% PROCESSED 75 ITERATIONS  
SEARCH TIME: 00.00.01


13 ANSWERS

L6 13 SEA SSS FUL L4

=> d scan

L6 13 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN 2H-1-Benzopyran-2,4(3H)-one, 3-[1-[(3,5-dichlorophenyl)methyl]-3-oxobutyl]-  
 , ion(1-), sodium (9CI)  
 MF C20 H15 Cl2 O4 . Na



● Na<sup>+</sup>

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d reg can tot

1	RN	749207-45-2	REGISTRY
2	RN	734532-29-7	REGISTRY
3	RN	732244-73-4	REGISTRY
4	RN	723242-03-3	REGISTRY
5	RN	673472-73-6	REGISTRY

REFERENCE 1: 140:264500

6	RN	673472-71-4	REGISTRY
---	----	-------------	----------

REFERENCE 1: 140:264500

7	RN	673472-69-0	REGISTRY
---	----	-------------	----------

REFERENCE 1: 140:264500

8	RN	673472-67-8	REGISTRY
---	----	-------------	----------

REFERENCE 1: 140:264500

9	RN	673472-65-6	REGISTRY
---	----	-------------	----------

REFERENCE 1: 140:264500

10	RN	673472-63-4	REGISTRY
----	----	-------------	----------

REFERENCE 1: 140:264500

11	RN	673472-61-2	REGISTRY
----	----	-------------	----------

REFERENCE 1: 140:264500

12	RN	673472-59-8	REGISTRY
----	----	-------------	----------

REFERENCE 1: 140:264500

13	RN	673472-57-6	REGISTRY
----	----	-------------	----------

REFERENCE 1: 140:264500

=> d 1 sub bib abs

L6 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN

RN 749207-45-2 REGISTRY


CN 2H-1-Benzopyran-2,4(3H)-one, 3-[1-[(3-chlorophenyl)methyl]-3-oxobutyl]-,  
 ion(1-) (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H16 Cl O4


CI COM

SR CA



=> d 1

L6 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 749207-45-2 REGISTRY  
IN 2H-1-Benzopyran-2,4(3H)-one, 3-[1-[(3-chlorophenyl)methyl]-3-oxobutyl]-,  
ion(1-) (9CI)  
MF C20 H16 Cl O4



=> fil beil

FILE 'BEILSTEIN' ENTERED AT 14:39:02 ON 29 SEP 2004  
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002  
FILE LAST UPDATED ON JUNE 15, 2004

FILE COVERS 1771 TO 2003.

\*\*\* FILE CONTAINS 8,997,153 SUBSTANCES \*\*\*

>>>PLEASE NOTE: Reaction Data and substance data are stored in  
separate documents and can not be searched together in one query.  
Reaction data for BEILSTEIN compounds may be displayed  
immediately with the display codes PRE (preparations) and REA  
(reactions). A substance answer set retrieved after the search  
for a chemical name, a compounds with available reaction  
information by combining with PRE/FA, REA/FA or more generally  
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link  
between a BEILSTEIN compound and belonging reactions. For mo  
detailed reaction searches BRNs can be searched as reaction  
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*

\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*  
\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

NEW

\* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE  
SEARCHED, SELECTED AND TRANSFERRED.  
\* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,  
ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A  
COMPOUND AT A GLANCE.

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> d his

(FILE 'HOME' ENTERED AT 13:34:19 ON 29 SEP 2004)

FILE 'REGISTRY' ENTERED AT 13:34:30 ON 29 SEP 2004

L1 1 S LAETISPICINE/CN  
L2 0 S WARFRIN/CN  
L3 1 S WARFARIN/CN  
L4 STR  
L5 0 S L4  
L6 13 S L4 FUL

FILE 'BEILSTEIN' ENTERED AT 14:39:02 ON 29 SEP 2004

=> s 14 ful

FULL SEARCH INITIATED 14:39:17 FILE 'BEILSTEIN'  
FULL SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.04

L7 0 SEA SSS FUL L4

=> fil caplus

FILE 'CAPLUS' ENTERED AT 14:39:28 ON 29 SEP 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2004 VOL 141 ISS 14  
FILE LAST UPDATED: 28 Sep 2004 (20040928/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16

L8 1 L6

=> d cbib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

2004:252198 Document No. 140:264500 Safer anticoagulant effect of coumarin analog compounds. Carter, Daniel C. (USA). U.S. Pat. Appl. Publ. US 2004058985 A1 20040325, 13 pp. (English). CODEN: USXXCO. APPLICATION: US 2003-629858 20030730. PRIORITY: US 2002-PV399126 20020730.

AB The invention discloses the albumin-guided development of coumarin analogs which can be used as safer and more effective alternatives to previous analogs such as sodium warfarin. The coumarin analogs of the invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The invention also discloses methods of providing anticoagulant and antithrombotic treatment utilizing effective amts. of the coumarin analogs which will have reduced potential for unfavorable drug interactions, reduced metabolic complications, and improved controllability within their therapeutic range. Together, the coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a min. of metabolic complications and undesirable side effects.

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.43	196.70

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.70	-1.36

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 14:40:33 ON 29 SEP 2004

=> d his

(FILE 'HOME' ENTERED AT 09:23:12 ON 30 SEP 2004)

FILE 'REGISTRY' ENTERED AT 09:23:22 ON 30 SEP 2004

L1 STR  
L2 0 S L1  
L3 STR L1  
L4 0 S L3  
L5 STR L3  
L6 0 S L5  
L7 3 S L5 FUL


FILE 'CAPLUS' ENTERED AT 09:34:21 ON 30 SEP 2004

L8 1 S L7

=> d sia l5

L5 HAS NO ANSWERS

L5 STR



O~C~O  
26 @27 28

VAR G1=24/27/ME/ET/N-PR/I-PR

NODE ATTRIBUTES:

HCOUNT IS M1 AT 24

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE